|This article needs additional citations for verification. (December 2009)|
|Systematic (IUPAC) name|
|Licence data||EMA: , US FDA:|
|Biological half-life||7.1-10.6 hours|
|CAS Registry Number|
|Molecular mass||505.628 g/mol|
|(what is this?)|
Amprenavir (Agenerase, GlaxoSmithKline) is a protease inhibitor used to treat HIV infection. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200 mg, delivered in 8 (eight) very large 150 mg gel capsules or 24 (twenty-four) 50 mg gel capsules twice daily.
Research aimed at development of renin inhibitors as potential antihypertensive agents had led to the discovery of compounds that blocked the action of this peptide cleaving enzyme. The amino acid sequence cleaved by renin was found to be fortuitously the same as that required to produce the HIV peptide coat. Structure–activity studies on renin inhibitors proved to be of great value for developing HIV protease inhibitors. Incorporation of an amino alcohol moiety proved crucial to inhibitory activity for many of these agents. This unit is closely related to the one found in the statine, an unusual amino acid that forms part of the pepstatin, a fermentation product that inhibits protease enzymes.
R.D. Tung, M.A. Murcko, G.R. Bhisetti, U.S. Patent 5,558,397 (1996). The scheme shown here is partly based on that used to prepare darunavir and fosamprenavir due to difficulty in deciphering the patent.
- Fosamprenavir, a prodrug of amprenavir
- "Agenerase® (amprenavir) Capsules. Full Prescribing Information. Section Dosage and Administration" (PDF). US Food and Drug Administration (http://www.fda.gov). GlaxoSmithKline and Vertex Pharmaceuticals Inc. Retrieved 28 June 2015.
- "Agenerase® (amprenavir) Capsules. Full Prescribing Information. Section Dosage and Administration" (PDF). HIV Drug Resistance Database (http://hivdb.stanford.edu). GlaxoSmithKline, 2005. Retrieved 28 June 2015.
- Shen, C. H.; Wang, Y. F.; Kovalevsky, A. Y.; Harrison, R. W.; Weber, I. T. (2010). "Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters". FEBS Journal 277 (18): 3699–3714. doi:10.1111/j.1742-4658.2010.07771.x. PMC 2975871. PMID 20695887.
- Getman, D. P.; Decrescenzo, G. A.; Heintz, R. M.; Reed, K. L.; Talley, J. J.; Bryant, M. L.; Clare, M.; Houseman, K. A.; Marr, J. J. (1993). "Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere". Journal of Medicinal Chemistry 36 (2): 288. doi:10.1021/jm00054a014.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|